RT Journal Article
SR Electronic
T1 Trans-ethnic analysis reveals genetic and non-genetic associations with COVID-19 susceptibility and severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.04.20188318
DO 10.1101/2020.09.04.20188318
A1 Shelton, Janie F.
A1 Shastri, Anjali J.
A1 Ye, Chelsea
A1 Weldon, Catherine H.
A1 Filshtein-Somnez, Teresa
A1 Coker, Daniella
A1 Symons, Antony
A1 Esparza-Gordillo, Jorge
A1 Team The 23andMe COVID-19 Team
A1 Aslibekyan, Stella
A1 Auton, Adam
YR 2020
UL http://medrxiv.org/content/early/2020/09/07/2020.09.04.20188318.abstract
AB COVID-19 presents with a wide range of severity, from asymptomatic in some individuals to fatal in others. Based on a study of over one million 23andMe research participants, we report genetic and non-genetic associations with testing positive for COVID-19, respiratory symptoms, and hospitalization. Risk factors for hospitalization include advancing age, male sex, elevated body mass index, lower socio-economic status, non-European ancestry, and pre-existing cardio-metabolic and respiratory conditions. Using trans-ethnic genome-wide association studies, we identify a strong association between blood type and COVID-19 diagnosis, as well as a gene-rich locus on chr3p21.31 that is more strongly associated with outcome severity. While non-European ancestry was found to be a significant risk factor for hospitalization after adjusting for socio-demographics and pre-existing health conditions, we did not find evidence that these two primary genetic associations explain differences between populations in terms of risk for severe COVID-19 outcomes.Competing Interest StatementAll authors identified as being part of 23andMe are current or former employees of 23andMe, Inc., and hold stock or stock options in 23andMe. JEG is an employee of GlaxoSmithKline and owns company stockFunding StatementNo external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participants provided informed consent and participated in the research online, under a protocol approved by the external AAHRPP-accredited IRB, Ethical & Independent Review Services (E&I Review).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full set of de-identified summary statistics can be made available to qualified investigators who enter into an agreement with 23andMe that protects participant confidentiality. Interested investigators should visit the following: https://research.23andme.com/covid19-dataset-access/. https://research.23andme.com/covid19-dataset-access